Skip to main content
JAMA Network logoLink to JAMA Network
. 2022 May 12;8(7):1073. doi: 10.1001/jamaoncol.2022.1721

Errors in Byline

PMCID: PMC9100444  PMID: 35551331

In the Brief Report titled “Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial,” published online July 1, 2021, and also in the August 2021 print issue of JAMA Oncology,1 Katherine M. Moxley, MD, was erroneously included in the byline, and Sagila George, MD, was mistakenly excluded. This article has been corrected online, and the Author Contributions section has been amended accordingly.1

References

  • 1.Rahma OE, Yothers G, Hong TS, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Oncology are provided here courtesy of American Medical Association

RESOURCES